1. Hybrid Androgen Receptor Inhibitors Outperform Enzalutamide and EPI‐001 in in vitro Models of Prostate Cancer Drug Resistance
- Author
-
Nicolescu, Radu Costin Bizga, Maylin, Zoe R, Pérez-Areales, Francisco Javier, Iegre, Jessica, Pandha, Hardev S, Asim, Mohammad, Spring, David R, Nicolescu, Radu Costin Bizga [0000-0003-2038-0672], Maylin, Zoe R [0000-0001-6647-213X], Pérez-Areales, Francisco Javier [0000-0001-9525-9346], Iegre, Jessica [0000-0002-9074-653X], Asim, Mohammad [0000-0002-2074-5929], Spring, David R [0000-0001-7355-2824], and Apollo - University of Cambridge Repository
- Subjects
Male ,Pharmacology ,enzalutamide, EPI-001 ,Organic Chemistry ,prostate cancer ,Biochemistry ,Prostatic Neoplasms, Castration-Resistant ,Receptors, Androgen ,Drug Resistance, Neoplasm ,androgen receptor ,Cell Line, Tumor ,Nitriles ,Drug Discovery ,Androgen Receptor Antagonists ,Humans ,Molecular Medicine ,General Pharmacology, Toxicology and Pharmaceutics ,dual inhibitors - Abstract
Funder: Prostate Cancer Foundation; Id: http://dx.doi.org/10.13039/100000892, Funder: UKRI; Id: http://dx.doi.org/10.13039/100014013, Funder: Trinity College Cambridge, Funder: University of Surrey PhD studentship award, Androgen receptor targeted therapies for prostate cancer have serious limitations in advanced stages of the disease. While resistance to the FDA-approved enzalutamide is extensively documented, novel therapies based on epichlorohydrin scaffolds (EPI) are currently in clinical trials, but display suboptimal pharmacokinetics. Herein, we report the synthesis and biological characterisation of a novel class of compounds designed through covalently linking enzalutamide and EPI-001 through various triazole based linkers. The compounds display an 18 to 53 fold improvement in the cell killing potency towards C4-2b prostate cancer (PCa) cells compared to the gold standards of therapy, enzalutamide and EPI-001. The most promising compounds were proven to exhibit their toxicity exclusively through androgen receptor (AR) mediated pathways. This work sets the basis for the first class of hybrid AR inhibitors which successfully combine two drug moieties - EPI-001 and enzalutamide - into the same molecule.
- Published
- 2022